INCJ and 10 portfolio companies in the health and medical field to jointly exhibit at BioJapan 2019

Tokyo, September 25, 2019 – INCJ, Ltd. (“INCJ”) announced today its decision to exhibit at BioJapan 2019, for 3 days between October 9 (Wed.) – 11 (Fri.) at Pacifico Yokohama. BioJapan is an Asia’s premier partnering event for the global biotechnology industry started in 1986. Over 1,000 organizations from around 34 countries are expected to participate in the event in the areas such as drug discovery, personalized medicine, regenerative medicine, diagnostic medical equipment, healthcare, environment/energy, functional foods, research equipment and reagent.

In April 2014, INCJ established a new specialist team covering the health and medical field, which focuses on proactive investment in bio venture companies and supporting the formation and commercialization of ecosystems in this field. INCJ has made a total of 142 investments, of this 114 were venture investments and 24 were in the health and medical field. (Figures are as of August 2019.)

INCJ will co-exhibit with its 10 portfolio companies in the health and medical field. Within the exhibition booth, INCJ will showcase panels and posters introducing each company’s business outline and technology in order to increase the understanding and awareness of visitors. INCJ will continue to focus on investment activities in the health and medical field and support the steady increase of the value of its portfolio companies and their businesses.

About BioJapan 2019
Event time and date October 9 (Wed.) -11 (Fri.) 2019
10:00 ~ 17:00 (Partnering from 8:30)
Location Pacifico Yokohama, Exhibition Hall B/C/D/Annex Hall
1-1-1 Minato Mirai, Nishi-ku, Yokohama
Website https://www.ics-expo.jp/biojapan/en/
INCJ exhibition booth location B-7
Co-exhibitors

- INCJ, Ltd.
- Anaeropharma Science, Inc.
  (Development of anti-cancer drugs based on i-DPS platform technology utilizing recombinant Bifidobacterium)
- Embrace Co., Ltd.
  (Communication platform for the community-based integrated care system)
- SCIVAX Corporation
  (Development and contract manufacturing of nanoimprinting machinery and processes)
- SCOHIA PHARMA, Inc.
  (Research and development for renal, metabolic and cardiovascular related medicines)
- Stella Pharma Corporation
  (Development of boron-based drugs used for Boron Neutron Capture Therapy)
- NanoMist Technologies Co., Ltd.
  (Develops and provides mist-based liquid separation / concentration technology and applied facilities)
- NapaJen Pharma, Inc.
  (Development of nucleic acids using unique drug delivery technology)
- Microwave Chemical Co., Ltd.
  (R&D, manufacture, engineering and sales including licensing of microwave chemical processes)
- Megakaryon Corporation
  (Development of induced pluripotent stem cell (iPSC)-derived platelet products)
- Rena Therapeutics Inc.
  (Support of drug discovery centered on heteroduplex oligonucleotide technology)

About INCJ, Ltd.

INCJ, Ltd. was established in September 2018 via company split from Innovation Network Corporation of Japan (INCJ). INCJ was established in July 2009 with the aim of overcoming boundaries between companies and industries, creating and nurturing key industries via open innovation for the prosperity of future generations, and the company has changed its name to Japan Investment Corporation (JIC) and begun new activities. INCJ, Ltd. will continue the activities of INCJ, engaging in “Value Up” activities such as overseeing additional investments, milestone investments and exits from investments in portfolio companies until March 2025.

URL: [http://www.incj.co.jp/english/](http://www.incj.co.jp/english/)

<Press Contacts>
Japan Investment Corporation
Communications Office: Irie, Sakai
Tel. (03) 5218-7202